Thursday, January 04, 2007 8:00:00 AM PDT | VentureDeal Staff
-- CoGenesys, a Human Genome
Sciences spinoff, has filed to begin human trials in Europe
for its Neugranin drug.
The drug is designed to treat patients with infections received as a result of
chemotherapy drugs. The first test will dose patients about to undergo
breast cancer chemotherapy.
The company also recently launched human trials for Cardeva, its heart failure
drug. It is also working on an insulin in earlier stages of development.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
Founded in 2006, VentureDeal is a database that provides the latest information about venture capital firms, venture-backed technology companies and transactions throughout North America.
Learn More »
Email Sign Up
© 2016 VentureDeal, Inc., Menlo Park, CA. All Rights Reserved.